Oppenheimer analyst Matthew Biegler reiterated a Perform rating on Fate Therapeutics (NASDAQ: FATE).The analyst commented, "Fate put out data this ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE